Guidance, NICE advice and quality standards in development | Guidance

Showing 161 to 170 of 391

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	10 September 2026
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	4 March 2026
Insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock	Interventional procedures guidance	25 March 2026
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance	TBC
Insulin efsitora alfa for treating type 2 diabetes ID6499	Technology appraisal guidance	TBC